Ernexa Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
71.7%projected annual EPS growth
Analyst Coverage
1analyst covering
FY EPS (est.)
-$18.02next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Operational Update | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
IND Submission Timeline for ERNA-101 QuarterlyTarget: Q3 2026
First-in-Human Phase 1 Study Initiation for ERNA-101 QuarterlyTarget: Q4 2026
Cash and Cash Equivalents Quarterly9.2MTarget: Sufficient to fund clinical transition
Watch Items
- FDA IND Clearance for ERNA-101Trigger: FDA approval of IND application in Q4 2026Action: Initiate Phase 1 clinical trial in platinum-resistant ovarian cancer
- Cash Runway and Capital DilutionTrigger: Cash balance falling below $5.0 millionAction: Utilize the established $50 million shelf registration and at-the-market (ATM) program to raise up to $9.2 million
- Nasdaq Minimum Bid Price ComplianceTrigger: Maintaining bid price above $1.00 post-reverse splitAction: Monitor stock price following the 1-for-25 reverse split executed on May 4, 2026
Research as of 20 Jun 2026